Drug shows promise for Down syndrome

Feb 26, 2007

Researchers at California's Stanford University report a drug known as PTZ can improve the learning and memory of lab mice with Down syndrome.

After receiving once-daily doses of PTZ, or pentylenetetrazole, researchers found the Down syndrome mice could recognize objects and navigate mazes as well as normal mice, The Los Angeles Times reported.

The improvements lasted up to two months after the drug was discontinued according to a report by the researchers in the journal Nature Neuroscience.

Lead author Craig C. Garner, a professor at the Stanford School of Medicine, told the Times that after more preliminary studies his lab will prepare for conducting human trials.

Down syndrome is the leading cause of mental retardation. It results from an extra copy of chromosome 21.

Copyright 2007 by United Press International

Explore further: Determine patient preferences by means of conjoint analysis

add to favorites email to friend print save as pdf

Related Stories

Time is of the essence

Feb 05, 2014

New findings in mice suggest that merely changing meal times could have a significant effect on the levels of triglycerides in the liver. The results of this Weizmann Institute of Science study, recently ...

Orbital samples with sight-saving potential

Dec 11, 2013

Those who travel to space are rewarded with a beautiful sight - planet Earth. But the effects of space travel on the human sense of sight aren't so beautiful. More than 30 percent of astronauts who returned ...

A protein that can mean life or death for cells

Sep 17, 2013

Each cell in an organism has a sensor that measures the health of its "internal" environment. This "alarm" is found in the endoplasmic reticulum (ER), which is able to sense cellular stress and trigger either ...

Analytical trick accelerates protein studies

Feb 24, 2013

Researchers at the University of Wisconsin-Madison have found a new way to accelerate a workhorse instrument that identifies proteins. The high-speed technique could help diagnose cancer sooner and point to new drugs for ...

Recommended for you

Determine patient preferences by means of conjoint analysis

17 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0